Drug Coating Surface Modification via Neutral Beam Irradiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug-eluting medical devices, such as stents, face issues with drug release control, toxicity from polymer coatings, and complications like restenosis due to thrombosis and scar tissue formation, which are not adequately addressed by existing technologies.
Innovation Solution
The use of accelerated Neutral Beam technology to process drug coatings on medical devices, eliminating the need for polymer binders and controlling drug release rates by modifying the surface layer of the drug coating to form a barrier that regulates elution and diffusion.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If polymer coatings are used to deliver drugs on medical devices, then drug delivery capability is improved, but toxicity and delamination of polymer flakes occur causing harmful effects
Solution Approach 1:
The patent extracts and removes the polymer binder from the drug coating system, leaving only the active drug substance on the medical device surface. This eliminates the toxic polymer flakes that cause delamination while preserving the drug delivery function through direct drug-device contact or alternative binding mechanisms.
Solution Approach 2:
The patent applies different properties to different regions of the coating system - the drug is localized directly on the device surface with controlled release properties, while the harmful polymer matrix is completely removed. This creates a localized drug delivery system with improved safety profile.
2Quantity of substance
If thick polymer coatings are applied to contain sufficient medicine, then drug load capacity is improved, but stent rigidity increases making expansion difficult
Solution Approach 1:
By removing the polymer binder entirely, the patent eliminates the source of excessive rigidity that thick polymer coatings impose on the stent structure. The drug is delivered through a thin layer or direct loading method, maintaining stent flexibility and expandability while achieving sufficient drug load capacity.
3Manufacturing precision
If conventional ion beams are used to process drug coatings, then surface modification capability is improved, but damage to insulating drug materials occurs due to charge accumulation
Solution Approach 1:
Instead of using charged ion beams that cause damage to insulating drug materials, the patent inverts the approach by using neutral particle beams. This neutral beam technology provides surface modification capabilities without the harmful charge accumulation effects, preserving drug material integrity while achieving desired surface properties.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enhances the control over drug release rates, reduces toxicity, and prevents delamination of polymer flakes, leading to improved medical device performance and patient outcomes by ensuring consistent and prolonged therapeutic effects.
Implementation Method 1
The use of accelerated Neutral Beam technology to process drug coatings on medical devices, eliminating the need for polymer binders and controlling drug release rates by modifying the surface layer of the drug coating to form a barrier that regulates elution and diffusion
Data Source
AI summary
A method of modifying the surface of a medical device to release a drug in a controlled way by providing a barrier layer on the surface of one or more drug coatings. The barrier layer consists of modified drug material converted to a barrier layer by irradiation by an accelerated neutral beam derived from an accelerated gas cluster ion beam. Also medical devices formed thereby.